StockNews.AI
MLYS
StockNews.AI
165 days

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

1. Mineralys will announce pivotal trial results on March 10, 2025. 2. The Launch-HTN trial evaluates lorundrostat for uncontrolled hypertension. 3. Advance-HTN trial tests lorundrostat with standardized hypertension treatments. 4. Positive trial results could boost MLYS's stock performance significantly. 5. Lorundrostat targets major health issues like hypertension and chronic kidney disease.

4m saved
Insight
Article

FAQ

Why Bullish?

Pivotal trial results are high-stakes; positive outcomes could lead to significant market interest, similar to other biotech companies that surged after successful trial announcements.

How important is it?

The results from these trials are crucial for MLYS's future growth and market valuation. Successful outcomes could substantially elevate investor interest and confidence.

Why Short Term?

The upcoming results on March 10 will have immediate market reactions, often influencing stock prices significantly in the short span before and after announcements.

Related Companies

AMGNPFEJNJ
March 07, 2025 16:01 ET  | Source: Mineralys Therapeutics, Inc. RADNOR, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will host a conference call and webinar to announce topline results from its Launch-HTN and Advance-HTN pivotal trials on Monday, March 10, 2025, at 8:00 a.m. ET. The Launch-HTN trial evaluated the efficacy and safety of lorundrostat, a highly selective aldosterone inhibitor, for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) as an add-on therapy to an existing, prescribed background treatment of two to five antihypertensive medications. The Advance-HTN trial evaluated the efficacy and safety of lorundrostat for the treatment of uHTN or rHTN when used as an add-on therapy to a standardized background treatment of two or three anti-hypertensive medications. Monday, March 10th@ 8:00 a.m. ETDomestic:1-877-704-4453International:1-201-389-0920Webcast:Link A live webcast of the conference call may also be found on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website. About Mineralys TherapeuticsMineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter. Contact: Investor Relationsinvestorrelations@mineralystx.com Media RelationsTom WeibleElixir Health Public RelationsPhone: (1) 515-707-9678Email: tweible@elixirhealthpr.com

Related News